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Abstract Chronic obstructive pulmonary disease (COPD) is a disabling condition associated with progressive airflow 
limitation that is largely irreversible, with symptoms of dyspnoea, cough and sputum production. In the Netherlands, COPD 
tends to be underpresented to physicians, underdiagnosed and under-treated by healthcare professionals, and poorly 
recognized among the general population. Improving the diagnosis and management of COPD in this country may require 
raised awareness of the impact of the disease on society.This may be achieved by providing detailed information on the 
burden of COPD on the patient, healthcare system and the economyThis information has now become available from 
Confonting COPD in North America and Europe, the first international survey to quantify the country-specific impact of the 
disease. An economic analysis of the results of the Dutch survey revealed the high cost of COPD to the healthcare system 
and society, with direct costs estimated at e6 I4 per patient. Indirect costs amounted to E4 IO, bringing the annual per 
patient cost of COPD to E 1024. Around 50% of the cost of COPD to the healthcare system was for prescription 
medication, including symptomatic medication and treatment for underlying airway inflammation. This contributed to 
effective symptom control in many patients, as shown by the low utilization of unscheduled healthcare (inpatient 
hospitalizations, emergency room visits, or contacts with healthcare professionals). However;  the survey suggested that there 
was scope for improvement in the understanding of the origin and consequences of this disease among the general public, 
and the way COPD is managed by healthcare professionals, in order to increase the proportion of patients who are 
diagnosed with COPD and treated in accordance with management guidelines. In addition, smoking cessation intervention 
at the early stages of the disease could help to reduce the high costs associated with severe COPD in this country, 
0 2003 Elsevler Science Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a 
disabling condition associated with progressive airflow 
limitation that is largely irreversible, with symptoms of 
dyspnoea, cough and sputum production. Tobacco 
smoking is the single most important cause of the 
disease (I). In the Netherlands, it is difficult to quantify 
how many people are affected with COPD, as little 
differentiation has been made between COPD and 
asthma, either by physicians or by researchers 
conducting epidemiological studies in the general 
population (2). However,  based on patient data from 
general practice registers, the overall prevalence of 
COPD was estimated at 2.4% for men, and I .4% for 
women in 2000.The prevalence of the disease increases 
with age, with the highest rates seen in people over the 
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age of 75 years (I 6% in men and 4.4% in women) (3). A 
modelling analysis that assessed the future burden of 
COPD in the Netherlands predicted that changes in the 
size and composition of the population would increase 
the prevalence of COPD to 3.3% in men and 2.3% in 
women by 20 I5 (a 59% increase in COPD prevalence in 
men and a 123% increase in women from the 1994 
figures) (3). When smoking patterns were taken into 
account, the predicted prevalence rate dropped to 2.9% 
for men (due to recent decline in the proportion of men 
who are smoke), but rose to 2.5% in women (reflecting 
the long-term cumulative impact of an increase in 
smoking prevalence among women over the past few 
decades). 
COPD causes considerable mortality and morbidity 
worldwide, and is predicted to become the fourth 
leading cause of death and the fifth leading cause of 
disability by the year 2020 (4). Studies in other countries 
have shown that mortality and morbidity from COPD 
has an impact on the society, in terms of the direct costs 
associated with healthcare resource use, and indirect 
costs due to lost productivity resulting from illness, 
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disability and premature death (5-7). In the Netherlands, 
studies that have attempted to assess the burden of 
COPD have focused on direct costs. A prevalence-based 
cost-of-illness study estimated the total direct costs of 
COPD and asthma at US$346 million in 1993, with an 
annual cost of US$876 per patient with COPD, 
compared with US$499 for asthma (8). When the costs 
of asthma and COPD were entered into a lifetime 
epidemiological model, it was estimated that the direct 
cost of these diseases would rise by 60% by the year 
2010, to US$555 mil1ion.A modelling analysis based on 
prevalence data and smoking rates estimated that the 
direct cost of the disease in the Netherlands would rise 
by 90% between 1994 (US$300 million) and 20 I5 
(US$580 million), primarily as a result of healthcare 
resource utilization in current or former smokers with 
the disease (3). 
The results of the cost-of-illness study described 
above revealed that the majority of costs for COPD 
were associated with hospital care (COPD accounted 
for 86% of inpatient costs for asthma and COPD 
combined) (8). The higher costs of hospitalization for 
patients with COPD compared with asthma were due to 
the higher number of inpatient days (381 194 versus 99 
I 14) and, in particular, a longer duration of hospital stay 
(I 6.0 days versus 9.2 days). As acute exacerbations of 
COPD are a major cause of inpatient hospitalization, 
these results suggest that improved management of 
exacerbations in primary care may reduce the burden of 
COPD on the healthcare system. A study of physician 
practices in the Netherlands in 1998 showed that the 
management of COPD exacerbations in primary care did 
not concord with Dutch management guidelines, with 
overutilization of antibiotic therapy, and only limited use 
of anti-inflammatory medications (inhaled and systemic 
corticosteroids) (9). 
The underpresentation of patients to physicians, and 
the underdiagnosis and subsequent undertreatment of 
COPD may also contribute to the burden of the disease 
in the Netherlands. It has been estimated that more than 
50% of patients with asthma/COPD do not recognize 
that they have a disease so do not present to a physician, 
so they remain undiagnosed and do not receive 
prescribed medication to control the chronic symptoms 
of the disease (IO). In a recent survey of the Dutch 
population, 95% of people questioned did not know what 
COPD was (I I). Even when patients do contact their 
physician, COPD may go undetected or be misdiagnosed 
as asthma, as lung function tests are rarely conducted in 
primary care (I 2). 
improving the diagnosis and management of COPD in 
the Netherlands may rely on raising awareness about the 
impact of the disease on society.This may be achieved by 
providing detailed information on the burden of COPD 
on the patient, healthcare system and the economy.This 
information has now become available from Confronting 
COPD in North America and Europe, the first international 
survey to quantify the country-specific impact of the 
disease.The survey interviewed patients and physicians in 
eight countries, to collect information on clinical 
outcomes, healthcare resource utilization and direct 
costs, COPD-related productivity loss, and indirect costs 
resulting from patient work absence.The clinical results 
of the survey showed that many patients with COPD 
were underdiagnosed and undertreated, and suffered 
frequent and disabling symptoms that reduced their 
quality of life (I 3).This paper reports the results of the 
economic analysis of the data on healthcare resource 
utilization and lost productivity in the Netherlands. 
METHODS 
Survey details 
The methodology for economic analysis of the 
Confronting COPD survey is described elsewhere (14). 
In brief, telephone interviews were conducted with a 
total of 3265 patients with COPD and 905 physicians in 
the Netherlands and seven other countries (Canada, 
France, Germany, Italy, Spain, the U.K., and the U.S.A.). 
Patient responses to the survey questionnaire were used 
to derive quantitative measures of COPD-related 
healthcare resource use and lost productivity. Direct, 
indirect and total societal costs per patient were 
calculated for the survey sample from each country (with 
the exception of Germany).A sub-analysis of costs was 
conducted for patient groups stratified by disease 
severity, sex, smoking status, comorbidity and education 
level. 
Cost calculations 
The unit costs used in the economic analysis of the 
survey data from the Netherlands are shown in Table I. 
Unit costs for lost productivity were applied to patients 
below the age of 62 years (the standard age of 
retirement for men and women in this country). The 
friction-cost method was used to calculate mean per 
patient costs of time lost from work, as described 
elsewhere ( 14). 
RESULTS 
Patient demographics 
Table 2 summarizes the demographics and clinical 
characteristics of the patients included in the economic 
analysis.The mean patient age was 61 years, and 46% of 
the patients in the sample were female.Around half of 
patients were current smokers, with a mean of 
approximately 35 pack years smoked.Around one-fifth of 
patients met the survey definition for chronic bronchitis 
(persistent cough and with phlegm or sputum 
production for the last 2years or more), but had not 
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been previously diagnosed with COPD. Of the patients 
who had been diagnosed, the mean age at diagnosis was 
44years. Less than one-third (30%) of patients reported 
comorbidities (of which the most frequently reported 
conditions were kidney problems, heart disease and 
arthritis). Most patients considered themselves to have 
mild or moderate COPD, but only one-quarter of patients 
reported that their condition was completely controlled 
with current medication.The majority of patients (72%) 
had been educated beyond basic schooling. 
Healthcare resource utilization 
Over half (55%) of the patients in the Netherlands 
sample of the Confronting COPD survey normally saw 
their primary care practitioner (PCP) for the overall 
management of their condition. A total of 1065 PCP 
visits were reported during the I2 month period prior 
to the survey. Although only 8% of patients in the 
survey reported unscheduled PCP visits, these visits 
accounted for one-fifth of the total number of PCP 
visits (Table 3). 
Two-fifths (42%) of patients in the sample were under 
specialist care for the treatment of their condition, and 
one-quarter of patients (27%) had seen a respiratory 
specialist at least three times in the past I2 months.The 
total number of specialist visits was 73 I, most of which 
were reported as either scheduled or unscheduled visits 
(Table 3). Unscheduled specialist visits were reported by 
4% of patients (mean seven visits per patient in this 
group), with a mean of 0.52 visits in the survey sample. 
Over one-quarter (27%) of patients in the survey 
reported that they had been hospitalized for COPD, with 
9% of patients having an in-patient stay in the last 
I 2 months. A total of I I4 hospitalizations were reported 
(Table 4). Emergency room visits were reported by 6% of 
patients, with I89 visits in the past year. 
Almost three-quarters (73%) of the patients in the 
Netherlands sample were currently receiving regular 
prescription medication for COPD. Inhaled cortico- 
steroids were the most commonly prescribed drugs, 
with short-acting &-agonists, anticholinergics and long- 
acting &-agonists received by over one-quarter of 
patients (Fig. I). One-fifth of patients had a nebulizer for 
drug administration. Six patients were prescribed a 
smoking cessation aid (bupropion). 
Around two-fifths (38%) of patients had been treated 
with antibiotics for respiratory infections in the previous 
year.The mean number of courses per patient reporting 
antibiotic use was 2.24 (mean 0.86 for the entire survey 
sample).The majority of patients (71%) had an influenza 
vaccination in the previous year, aimed at preventing 
exacerbations of COPD. Home oxygen therapy for 
COPD was used by 4% of patients (n= IS) in the last 
I2 months, with 4 I35 days of use (mean 276 days use for 
each patient using oxygen therapy). 
The Confronting COPD survey also assessed the 
number of laboratory tests received by patients with 
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FIGURE I. Use of prescribed medications by patients in the Netherlands sample 
COPD. Overall, 749 tests were conducted in the survey 
sample (a mean of 1.8 tests per patient). The most 
commonly reported investigation was the chest X-ray, 
followed by tests of blood oxygen levels (Table 5). 
Time lost from work 
Over half (60%) of patients in the Netherlands survey 
sample were under the age of retirement. Just under 
one-fifth (18%) of patients reported that they were 
completely prevented from working due to COPD, and 
one in ten patients (10%) reported that they were 
limited in their work during the I2 months prior to the 
survey.A further 3% of patients missed work as a result 
of their condition, with a total of 4894 days lost in the 
past year. Twelve patients (3%) reported that their 
caregiver missed work as a result of COPD, with a total 
of 65 days lost (mean 5.4 days per caregiver). 
Direct costs 
Based on measures of healthcare resource utilization, the 
mean annual direct cost of COPD was estimated at 
E6 13.92 per patient. Almost three-fifths of these costs 
were accounted for by treatment for COPD (mean 
8359.70 per patient), of which prescription medication 
amounted to e300.93 (Fig. 2, Table 6). Unscheduled 
emergency care for COPD (inpatient hospitalizations, 
emergency room visits, unscheduled PCP and specialist 
visits) accounted for over one-fifth (2 I%) of costs, 
compared with 16% of total costs for scheduled visits to 
a healthcare professional (Fig. 2). Specialist visits 
accounted for a higher proportion of direct per patient 
costs than inpatient hospitalizations, emergency room 
treatment, or PCP visits alone (Table 6). Laboratory tests 
for COPD accounted for under 4% of direct costs, at a 
mean cost of 822.05 per patient. 
Indirect and total societal costs 
The results of the Confronting COPD survey in the 
Netherlands revealed that patient work loss due to 
COPD cost an estimated E409.70 per patient over a 
I2-month period.When the indirect cost of COPD was 
added to the direct cost (see above), the societal cost of 
COPD was estimated at +Z 1023.62 per patient. 
Costs sub-analysis 
A sub-analysis of direct, indirect and societal costs was 
carried out to assess the economic impact of COPD in 
relation to disease severity. The results showed that 
patients with severe COPD (either self-perceived or 
assessed using the Medical Research Council Dyspnoea 
Scale) had consistently higher costs than patients with 
moderate or mild COPD (Fig. 3). 
Costs were also assessed in relation to patient sex, 
smoking status, comorbidity and education level. The 
results showed that direct, indirect, and societal costs per 
patient were higher for male patients, former smokers, 
patients with comorbidities and patients with no 
education beyond basic schooling, compared with female 
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FIGURE 2. Percentage breakdown of annual direct costs of COPD for the Netherlands sample. 
patients, current smokers, patients with no comorbidities, direct and indirect costs in patients with diagnosed 
and educated patients, respectively (Table 7). COPD, chronic bronchitis or emphysema, or 
undiagnosed COPD (chronic bronchitis, as defined by 
DISCUSSION chronic cough with sputum production for at least 
2 years). The results of the survey conducted in the 
The Confronting COPD survey assessed healthcare Netherlands showed the high cost of COPD to the 
resource utilization, lost productivity and associated healthcare system and society. The direct cost of the 
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FIGURE 3. Societal costs of COPD by disease severity 
disease was estimated at ‘Z6 I4 per patient, while patient 
work loss amounted to 8410, bringing the annual per 
patient cost of COPD to +Z 1024. 
Over half of the patients in the Netherlands sample 
reported that they normally saw a primary care 
practitioner for the treatment of their condition.Two- 
fifths of patients were also under specialist care. Seven of 
ten COPD patients in the current survey had received an 
influenza vaccination in the previous year. Regular 
prescription medication for COPD was reported by 75% 
of patients in the survey, and inhaled corticosteroids 
were the most commonly prescribed medication class 
(being reported by almost half of the patients in the 
survey sample).The use of inhaled corticosteroids in the 
treatment of COPD is widely accepted in the 
Netherlands, based on the concept of treating the 
inflammatory component of COPD, with the aim of 
reducing exacerbations of this disease (I 5).This concept 
has now been included in the General Practitioner 
guidelines for the diagnosis and the treatment of COPD 
in this country (I 6-l 7). 
Aside from inhaled corticosteroids, over one-quarter 
of patients in the survey reported treatment with short- 
acting PI-agonists, anticholinergics and long-acting 
&-agonists. The results of the survey suggested that 
treatment of the symptoms and the underlying airway 
inflammation in COPD may lead to effective disease 
control. Fewer than one in ten patients in the survey had 
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been hospitalized for COPD in the previous year, and 
hospitalization accounted for only 12% of the direct 
costs of the disease, compared with 50% for regular 
prescription medication. This contrasts with previous 
cost-of-illness studies conducted in the Netherlands, 
where the majority of direct costs were for 
hospitalization (8). Although the apparent shift from 
hospitalizations to medication as a major cost driver 
could have resulted from restrictive hospitalization 
policy, or different definitions of COPD being adopted 
during the period between this and previous studies, the 
low rate of hospitalization in the current survey was 
accompanied by a low number of unscheduled visits to 
physicians (l3), suggesting that improved control of 
COPD symptoms with bronchodilator and anti- 
inflammatory medications was a contributory factor. 
Only a small proportion of patients in the survey 
reported unscheduled care for COPD (i.e. hospitaliza- 
tions, emergency room visits and unscheduled contacts 
with healthcare professionals). Recognizing that COPD is 
a heterogeneous disease, it is possible that in these 
patients, the underlying aetiology of COPD is such that 
current treatment is unable to prevent unscheduled 
events. Research is required to investigate this further. 
Identifying sub-groups of patients who may be 
unresponsive to treatment could be important from a 
healthcare evaluation perspective, as disease aetiology 
and the lack of effective treatment, rather than healthcare 
services provided, may determine outcomes in these 
patients. If such sub-groups of patients were identified, 
developing effective treatments to prevent unscheduled 
events could reduce the economic impact of COPD in 
the Netherlands, as over one-fifth of direct per patient 
costs in the survey were due to unscheduled care. 
One-fifth of patients in the survey had not been 
diagnosed with COPD, and were presumably not 
receiving regular prescribed treatment for the chronic 
symptoms of the disease. Both from a healthcare and an 
economic perspective, reducing the number of 
undiagnosed COPD patients could play an important 
role in alleviating the burden of this disease. Many 
patients may remain undiagnosed because they do not 
present to a physician with symptoms of the disease. 
Therefore, an increased understanding of the origin, the 
consequences and treatment of COPD among the 
general public could help to increase the number of 
patients who receive a diagnosis. 
A study conducted in I998 among 24 primary care 
practitioners in the Netherlands revealed barriers to the 
implementation of guideline recommendations for 
asthma/COPD. However, by monitoring physicians and 
providing them with feedback on their provision of care, 
physicians showed improvement in their knowledge and 
skills surrounding diagnosis and treatment of COPD, 
with an increase in the monitoring of lung function, the 
use of influenza vaccination to prevent respiratory 
infection, and the treatment of exacerbations with anti- 
inflammatory medications, rather than antibiotics (9,I2). 
These results suggest that recognizing the nature of 
barriers to the implementation of guidelines and 
developing initiatives to overcome them will contribute 
to improved primary care provision for COPD patients. 
The sub-analysis of costs from Confronting COPD in 
the Netherlands showed that the direct, indirect and 
total societal costs of COPD were considerably higher in 
patients with severe disease than patients with mild or 
moderate COPD. This suggests that interventions that 
could effectively delay the progression to severe COPD 
could reduce the costs of the disease. At present, 
smoking cessation in the early stages of COPD is the 
only intervention proven to delay the long-term decline 
in lung function in these patients. The importance of 
smoking cessation in patients with COPD has already 
been highlighted by an analysis of the future burden of 
the disease in the Netherlands, which estimated that 
smoking behaviour would account for 90% of the 
increase in direct costs that is predicted to occur by 
20 I5 (3). 
CONCLUSION 
COPD is a disease that places a high burden on the 
healthcare system and society in the Netherlands. Unlike 
in previous studies, treatment for COPD accounted for 
a significant proportion of costs of COPD to the 
healthcare system, and the burden of COPD on 
unscheduled emergency care was relatively low. The 
survey suggested that there is scope to improve the 
proportion of diagnosed COPD patientsThis could be 
achieved by increasing the understanding of the origin 
and the consequences of this disease among the general 
public. Recognizing and developing strategies to 
overcome barriers to the implementation of treatment 
guidelines would support the provision of improved 
primary care services for COPD. In addition, smoking 
cessation intervention at the early stages of the disease 
could help to reduce the high costs associated with 
severe COPD in this country. 
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